Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: a placebo controlled, randomized, single-blind study

Kocatürk, Emek; Aktaş, Selin; Türkoğlu, Zafer; Kavala, Mukaddes; Zindancı, İlkin; Koç, Melek; Can, Burçe; Sudogan, Sibel

doi:10.3109/09546634.2011.593485

Cited by 37 publications

(33 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Autologous whole-blood injection (AWBI) has been proposed as a therapeutic intervention for the treatment of CSU; there are conflicting results concerning its effectiveness, but it does not have severe side effects [7,8]. …”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria

Kitsioulis

Xepapadaki

Roussaki-Schulze

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

Background: Nonsedating antihistamines are the treatment of choice for chronic spontaneous urticaria (CSU), while omalizumab and immunosuppressants have also been approved as an add-on treatment. Autologous whole-blood injection (AWBI) has been used in previous studies with ambiguous results. The aim of our study was to evaluatechanges in the Urticaria Activity Score (UAS7), Dermatology Life Quality Index (DLQI), and Chronic Urticaria Quality of Life (CU-Q₂oL) score, and also the association of serologic markers with disease severity measures after AWBI. Methods: In this observational study, AWBIs were performed (8 courses on a weekly basis) in adults with refractory CSU, who refused an add-on treatment with either omalizumab or immunosuppressants. UAS7, DLQI, and CU-Q₂oL questionnaires and serum concentrations of total IgE, C-reactive protein (CRP), and D-dimer were evaluated before and after the intervention. Results: Nineteen patients (12 females; mean age 54 ± 20.8 years) completed the protocol. Following AWBI, significant improvements in the UAS7 (34.26 ± 8.04 vs. 12.52 ± 10.83, p < 0.001), DLQI (11.63 ± 5.51 vs. 3.47 ± 2.85, p < 0.001), and CU-Q₂oL score (32.97 ± 18.71 vs. 10.94 ± 7.71, p < 0.001) were recorded. A negative correlation between the baseline D-dimer levels and UAS7 and DLQI variations (p = 0.002 and p = 0.001, respectively) was noted. D-dimer levels ≥292 ng/mL have been associated with poor responsiveness (sensitivity 75%; specificity 83.3%). No correlation with either total immunoglobulin E or CRP levels was observed. Conclusion: AWBI appears to be a safe, alternative, add-on therapeutic option in refractory CSU, particularly in patients with low plasma levels of D-dimer.

show abstract

Section: Introductionmentioning

confidence: 99%

Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria

Kitsioulis

Xepapadaki

Roussaki-Schulze

et al. 2017

Int Arch Allergy Immunol

View full text Add to dashboard Cite

show abstract

“…It was used in the therapy of chronic urticaria. Its efficacy in the reduction of disease activity and improvement in quality of life was shown in a randomized single blind study of chronic urticaria [10]. The autologous haemotherapy was also used for treatment of atopic dermatitis with the same efficacy [11].…”

Section: Discussionmentioning

confidence: 99%

Polymorphic eruption of pregnancy – new therapeutic approach

Part¹,

Gulanova²,

Šimaljaková³

2017

J Pregnancy Reprod

View full text Add to dashboard Cite

show abstract

“…Otkriće anti-IgG antitijela prema sopstvenom imunoglobulinu E ili njegovim receptorima visokog afiniteta dovelo je do pokuša-ja da se kao terapijski modalitet u liječenju hroničnih urtikarija koristi izazivanje tolerancije na cirkulirajući histamin primjenom autologne krvi ili seruma [10]. Ponovljene injekcije autologne krvi ili seruma mogu biti efikasne u liječenju hronične urtikarije.…”

Section: Uvodunclassified

“…Kocatürk sa saradnicima [10] u svojoj studiji od 88 bolesnika sa hroničnom urtikarijom, procjenjivao je efekat terapije autolognom punom krvi i autolognim serumom u poređenju sa placebom. Svim bolesnicima je uradio ASST.…”

Section: Diskusijaunclassified

Primjena autohemoterapije u liječenju hronične urtikarije

Baroš¹,

Gajanin²,

Sladojević³

et al. 2017

BII

View full text Add to dashboard Cite

Kratak sadržajUvod. U liječenju hronične urtikarije, osim standardnih protokola, može biti efikasna i primjena autohemoterapije. Cilj rada je utvrditi uspješnost autohemoterapije u liječenju hronične autoimunske urtikarije na težinu bolesti i prosječnu dužinu trajanja hronične urtikarije kod pacijenata liječenih u našoj ustanovi.Metode. Ispitivana su 64 bolesnika sa hroničnom urtikarijom tokom šest nedjelja. Ispitanici su podijeljeni u dvije grupe: 28 bolesnika sa autoimunskom hroničnom urtikarijom kojima su ordinirane standardna i autohemoterapija i 36 bolesnika sa idiopatskom hroničnom urtikarijom kojima je ordinirana samo standardna terapija. Terapijski uspjeh primjene autohemoterapije u liječenju hronične urtikarije smo pratili pomoću skora težine urtikarije (engl. Urticaria Severity Score -USS). Takođe, odredili smo prosječnu dužinu trajanja urtikarije. Za statističku analizu korišćeni su Mann-Whitney i Friedman-ov test, za nivo značajnosti razlike manje od 5%.Rezultati. Poređenjem vrijednosti USS utvrđena je statistički značajna razlika u visini nedjeljnog USS na početku i na kraju ispitivanja kod obje grupe bolesnika: kod bolesnika sa autoimunskom hroničnom urtikarijom (χ 2 = 122,130, p< 0,001) i kod bolesnika sa idiopatskom hroničnom urtikarijom (χ 2 = 137,827, p<0,001). Poređenjem vrijednosti USS između grupa bolesnika tokom prvih pet nedjelja praćenja nije utvrđena statistički značajna razlika. Međutim, u šestoj nedjelji je nađena statistički značajna razlika u USS između ispitivanih grupa (p = 0,032). Kod bolesnika sa autoimunskom hroničnom urtikarijom i idiopatskom hroničnom urtikarijom prosječna dužina trajanja urtikarije približno je iznosila 20 mjeseci i nema statistički značajne razlike u dužini trajanja urtikarije između grupa (p = 0,978).Zaključak. Autohemoterapija se pokazala efikasnom i uspješnom u liječenju autoimunske hronične urtikarije u odnosu na standardne protokole liječenja hronične urtikarije, ali ne utiče na dužinu trajanja urtikarije.

show abstract

Autologous whole blood and autologous serum injections are equally effective as placebo injections in reducing disease activity in patients with chronic spontaneous urticaria: a placebo controlled, randomized, single-blind study

Abstract: Even though we could not show a better efficacy than placebo, autohemotherapy resulted in a marked decrease in disease activity and improvement in quality of life scores in CU patients.

Cited by 37 publications

References 15 publications

Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria

Effectiveness of Autologous Whole-Blood Injections in Patients with Refractory Chronic Spontaneous Urticaria

Polymorphic eruption of pregnancy – new therapeutic approach

Primjena autohemoterapije u liječenju hronične urtikarije

Contact Info

Product

Resources

About